Professional Documents
Culture Documents
R Hemamalini
2010CYZ8795
Group G1
2.
Sources Enzyme treatment for special conditions Market Scenario Technologies for production
3.
Enzymes The
are
biological of
catalysts, action
usually are
proteins
that and
accelerate chemical reaction rates by a million fold or more. hallmarks enzyme specificity, efficiency. They are essential for cell and tissue viability. Clinical consequences result in their absence or malfunction.
4.
Specificity
Incentives
High affinity
Potent
5.
Long-term dependency
Immunogenic
Need encapsulation
High Purity
6.
The use of animal enzymes instead of microbial enzymes, although these would be costlier. Modified by covalent attachment of polyethylene glycol, for e.g in asparaginase Entrapment of the enzyme within artificial liposomes, synthetic microspheres and red blood cell ghosts. Choose the sources carefully to avoid any unwanted
7.
Enzymes in medicine
Prophylaxis
Diagnosis
Drug manufacture
Cancer
Wound healing
Lactose intolerance
Clotting Anti-clotting
8.
Alleviation of symptoms
9.
Adequate drugs for many of rare diseases and conditions have not been developed Orphan drugs Passed in 1983 in the United States Encourage pharmaceutical companies to develop treatments for
Source:- Stefano Villa, Amelia Compagni and Michael R. Reich (2008) Orphan drug legislation: lessons for neglected tropical diseases, Int J Health Plann Mgmt,2008
10.
Severe Combined Immunodeficiency (SCID) Autosomal recessive, frequent infections result in early death.
Intracellular
purine
metabolites
accumulate
to
toxic
concentrations within cell. T-cell and B-cell function absent from birth ADAGEN (Pegademase Bovine) Enzon Inc. Sigma-Tau Pharmaceutical Inc. modified enzyme for ERT derived from bovine intestine injections rh ADA developed by R&D systems, Minneapolis, but for research only, Feb, 2011.
12.
accumulation of SAH
Congenital sucrase-isomaltase deficiency (CSID) An autosomal recessive disease of the small intestine first discovered in 1960 by Weijers and colleagues. Sucrase and maltase activity absent or minimal. Sucrase replacement therapy with 100-fold more potent enzyme
Sucrosidase - Sucraid
Liquid form, Saccharomyces cerevisiae-derived, oral solution 8,500 I.U per ml of sucrase
14.
Deficiency of the above enzyme -> Phenylketonuria (PKU) Genetic disease Treatment from birth with a low phenylalanine diet. Phenyl alanine ammonia lyase - EC 4.3.1.5 acts as a substitute for the deficient enzyme. PAL,converts phenylalanine to trans-cinnamic acid, a harmless metabolite. Sources: Plants, recombinant Modified with PEG for stability
16.
Glucocerebrosidase - EC 3.2.1.45
17.
disease in 1965
by Brady et al..
O=C-CH2-CH2-CH2-(CH2)nCH3 OH N Glucose OH-CH2-CH-CH-CH=CH-(CH2)12CH3 Ceramide
The lack of the glucocerebrosidase, a - glucoronidase leads to accumulation of glucocerebroside. Autosomal recessive disorder Ceredase - ERT with - glucoronidase extracted from
19.
20.
Cellulase
Nattokinase Serratio-
peptidase
Proteolytic
21.
Bilirubin oxidase
Heparinase
Sucrase-isomaltase Ribonuclease T1 L-Asparaginase Collagenase Streptokinase Serratiopeptidase Uricase
22.
Microbial production
Plant cultivation
23.
24.
billion in 2010.
The market is growing at a compound annual growth rate (CAGR) of 3.9%, to reach $7.2 billion in 2015.
rate (CAGR) .
Enzymes used in molecular research will experience the fastest compound annual growth rate (CAGR), 6.2%, over the study
period. This sector was worth $546 million in 2010 and should
reach nearly $739 million by 2015.
Source: BCC Research on Medical Enzymes: Technology and Global Markets
25.
Total
enzyme
consumption
figures
of
India
are
government
interaction.
policies
to
promote
academic-industry
1. 2.
BCC Research on Medical Enzymes: Technology and Global Markets Cerezyme Imiglucerase for Injection http://www.cerezyme.com/~/media/Files/CerezymeUS/pdf/cerezyme_pi.pdf
3.
Christineh N. Sarkissian, Zhongqi Shao, Franc Oise Blain, Rosalie Peevers, Bongsheng Su,
Robert Heft, Thomas M. S. Chang and Charles R. Scriver, A different approach to treatment of phenylketonuria: Phenylalanine degradation with recombinant phenylalanine ammonia lyase, Proc. Natl. Acad. Sci. USA Vol. 96, pp. 23392344, March 1999
4.
D. R. HeadonAnd G. Walsh, The industrial production of enzymes, Biotech. Adv. Vol. 12, pp.
635--646,1994
5. David J. Saul, Moreland D. Gibbs and Peter L.Bergquist, Biocatalysis: Industrial Enzymes and the exploitation of micro-organisms, New Zealand Institute of Chemistry 6. Enzymes: EC Nomenclature 4th level Complete List of all Enzymes, http://www.biologie.uni-hamburg.de/b-online/e18_1/ec4.htm
7.
8.
9.
Michel Duval, Stefan Suciu, Alina Ferster, Xavier Rialland, Brigitte Nelken, Patrick Lutz, Yves Benoit, Alain Robert, Anne-Marie Manel, Etienne Vilmer, Jacques Otten and Nol Philippe, Comparison of Escherichia coli-asparaginase withErwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer--Children's Leukemia Group phase 3 trial, Blood, 15 April 2002 Volume 99, Number 8
10. 11.
Protein expression workflow by Sigma-Aldrich Rodney J.Y Ho, Milo Gibaldi (2003) in Biotechnology and Biopharmaceuticals, Wiley-Liss, NJ, pp. 245-269
12.
Stefano Villa, Amelia Compagni and Michael R. Reich (2008) Orphan drug legislation: lessons for neglected tropical diseases, Int J Health Plann Mgmt,2008
13.
Syndey Sandberg, Special Report: A nutraceutical approach to enhancing memory, Enzyme News
14. 15.
The Enzyme Revolution by Enzymedica Walsh, G (2003) in Biopharmaceuticals Biochemistry and Biotechnology, Wiley, West Sussex, 2nd Ed., pp. 351-402
Dr. Ravi Krishnan Elangovan for inspiring me to take up this topic Prof. S.K. Khare for his support and guidance